Elif PALA, Tuba DENKCEKEN

Identification of chemoresistance-associated miRNAs in hypopharyngeal squamous cell carcinoma

This study aimed to determine candidate miRNAs that could help to evaluate whether patients with hypopharyngeal squamous cell carcinoma (HSCC) would benefit from docetaxel, cisplatin, and 5-fluorouracil (TPF) induction chemotherapy. We downloaded the expression profiles of HSCC patients from the Gene Expression Omnibus database. miRNA profiles were analyzed via Principal Components Analysis (PCA), followed by Linear Discriminant Analysis (LDA). The Database Annotation for Visualization and Integrated Discovery tool was utilized for enrichment analysis; STRING and Cytoscape were used for network construction. We detected that hsa-miR-15b-5p, hsa-miR-93-5p, and hsa-miR-130a-3p might act as crucial regulators in chemoresistance of HSCC, and they may play as prognosticators and therapeutic targets in the future.

PDF

___

1. Takes RP, Strojan P, Silver CE, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head & Neck. 2012;34:270-281.

2. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J NTL Cancer I. 2009;101:498-506.

3. Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695-704.

4. Lian M, Shi Q, Fang J, et al. In vivo gene expression profiling for chemosensitivity to docetaxel-cisplatin-5-FU (TPF) triplet regimen in laryngeal squamous cell carcinoma and the effect of TPF treatment on related gene expression in vitro. Acta Otolaryngol. 2017;137:765-72.

5. Goksuluk D, Korkmaz S, Zararsiz G, et al. easyROC: An Interactive Web-tool for ROC Curve Analysis Using R Language Environment. The R Journal. 2016;8:213-230.

6. Abdi H and Williams LJ. Principal component analysis.WIREs Comp Stats. 2010;2:433-59.

7. Lachenbruch PA and Mickey MR. Estimation of error rates in discriminant analysis. Technometrics. 1968;10:1-11.

8. RStudio Team (2016). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA.

9. Haunsberger SJ, Connolly NM, and Prehn JH miRNAmeConverter: an R/bioconductor package for translating mature miRNA names to different miRBase versions. Bioinformatics. 2016;33:592-3.

10. Ru Y, Kechris KJ, Tabakoff B, et al. The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations. Nucleic Acids Res. 2014;42:e133-e133.

11. Huang DW, Sherman BT, and Lempicki RA Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2008;4:44.

12. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:607-13.

13. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498-504.

14. Brenning A and Lausen B Estimating error rates in the classification of paired organs. Stat Med. 2008;27:4515-31.

15. Fawcett T An introduction to ROC analysis. Pattern Recogn. Lett. 2006; 27:861-74.

16. Ma L and Weinberg RA MicroRNAs in malignant progression. Cell Cycle. 2008;7:570-2.

17. Ahmad P, Sana J, Slavik M, et al. MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy. Cancer Genom Proteom. 2019;16:139-46.

18. Ramdas L, Giri U, Ashorn C, et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck. 2009;31:642–54.

19. Cao P, Zhou L, Zhang J, et al. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck. 2013;35:720-8.

20. Yin W, Wang P, Wang X, et al. Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells. Braz J Med Biol Res. 2013;46:546-54.

21. Lindner K, Eichelmann AK, Matuszcak C, et al. Complex Epigenetic Regulation of Chemotherapy Resistance and Biology in Esophageal Squamous Cell Carcinoma via MicroRNAs. Int J Mol Sci. 2018;19:499.

22. Xu N, Shen C, Luo Y, et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem. Biophys. Res. Commun. 2012;425:468-72.

23. Li B, Huang P, Qiu J, et al. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosisMed. Oncol. 2014;31:230.

24. Chen X, Yue B, Zhang C, et al. MiR-130a-3p inhibits the viability, proliferation, invasion, and cell cycle, and promotes apoptosis of nasopharyngeal carcinoma cells by suppressing BACH2 expression. Biosci Rep. 2017;37:BSR20160576.